The possibility of perindopril in angioprotective in patients with metabolic syndrome after combination therapy with a thiazide diuretic

  • Authors: Nedogoda SV1, Smirnova VO1, Khripaeva VY.1, Palashkin RV1, Ledyaeva AA1, Chumachok EV1, Salasyuk AS1
  • Affiliations:
    1. Volgograd State Medical University of Ministry of Health of the Russian Federation
  • Issue: Vol 13, No 1 (2016)
  • Pages: 30-33
  • Section: Articles
  • URL: https://syst-hypertension.ru/2075-082X/article/view/29121
  • Cite item

Abstract


Aim. To assess the possibility of monotherapy with perindopril after transferring from combination therapy with losartan and hydrochlorothiazide with respect to correction of the anthropometric, metabolic parameters, premature vascular aging and vascular elasticity in patients with metabolic syndrome. Material and methods. Held open prospective controlled study of 50 patients with metabolic syndrome (IDF, 2005), which reached BP<140/90 mm Hg during three months of therapy with losartan (50 mg) + hydrochlorothiazide (12.5 mg) with conversion to monotherapy with perindopril 10 mg for 12 weeks. Patients were evaluated anthropometric and metabolic parameters, levels of adipokines, and indices of vascular elasticity and age was estimated on the date of the transfer with casinadirosa combination monotherapy with perindopril and after 12 weeks thereafter.Results. The results of the study demonstrated the possibility of a transfer with combination antihypertensive therapy monotherapy perindopril patients with metabolic syndrome that contributes to slow vascular aging, improve the elasticity of blood vessels, reduces inflammation and has a beneficial impact on adipokines.Conclusion. When achieved BP<140/90 mm Hg on combination with a thiazide diureticpossible in patients with MS monotherapy perindopril with consequent improvement in elasticity of blood vessels and of adipokines.

Full Text

Restricted Access

About the authors

S V Nedogoda

Volgograd State Medical University of Ministry of Health of the Russian Federation

Email: nedogodasv@rambler.ru
400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

V O Smirnova

Volgograd State Medical University of Ministry of Health of the Russian Federation

400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

V Yu Khripaeva

Volgograd State Medical University of Ministry of Health of the Russian Federation

400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

R V Palashkin

Volgograd State Medical University of Ministry of Health of the Russian Federation

400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

A A Ledyaeva

Volgograd State Medical University of Ministry of Health of the Russian Federation

400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

E V Chumachok

Volgograd State Medical University of Ministry of Health of the Russian Federation

400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

A S Salasyuk

Volgograd State Medical University of Ministry of Health of the Russian Federation

400131, Russian Federation, Volgograd, pl. Pavshikh bortsov, d. 1

References

  1. Niskanen L.D.E, Nyyssönen K, Punnonen et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004; 44 (6): 859-65.
  2. Brasier A.R, Recinos A, Mohsen S.E. Vascular inflammation and the renin - angiotensin system. Arteriosclerosis, Thrombosis, and Vascular Biology 2002; 22 (8): 1257-66.
  3. Blake G.J, Rifai N, Buring J.E et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108 (24): 2993-9.
  4. Sesso H.D, Buring J.E, Rifai N et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290 (22): 2945-51.
  5. Giuseppe M.G, Robert F, Narkiewicz К. ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013; 31: 1281-357.
  6. Ridker P.M, Danielson E, Rifai N et al. Valsartan, blood pressure reduction, and c - reactive protein primary report of the Val-MARC Trial. Hypertension 2006; 48 (1): 73-9.
  7. Кобалава Ж.Д., Котовская Ю.В., Рубанова А.А. Эффективность и переносимость стратегии «stepdown», основанной на телмисартане, в лечении больных артериальной гипертензией с метаболическим синдромом. Артериальная гипертензия. 2011; 17 (5).
  8. Rahman S.T, Lauten W.B, Khan et al. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin - angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002; 89 (6): 686-90.
  9. Fonseca F.A.H, Ihara S.S.M, Izar M.C.O et al. Hydrochlorothiazide abolishes the anti atherosclerotic effect of quinapril. Clin Experim Pharmacol Physiol 2003; 30 (10): 779-85.
  10. Nedogoda S.V, Ledyaeva A.A, Chumachok E.V et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig 2013; 33 (8): 553-61.
  11. Krysiak R, Sierant M, Marek B et al. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynol Pol 2010; 61 (6): 683-90.

Statistics

Views

Abstract - 15

PDF (Russian) - 6

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies